These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31060052)

  • 1. Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel.
    Duarte-García A; Matteson EL; Shah ND
    Ann Intern Med; 2019 Jun; 170(11):791-792. PubMed ID: 31060052
    [No Abstract]   [Full Text] [Related]  

  • 2. Is There Any Reliable Clinical Evidence to Suggest That Acthar Is More Effective Than Other Forms of Corticosteroids in Treating Sarcoidosis and Other Diseases It Is Being Marketed to Treat?
    Metersky ML
    Chest; 2016 Mar; 149(3):886. PubMed ID: 26836916
    [No Abstract]   [Full Text] [Related]  

  • 3. Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel(®).
    Gold LS; Schepman PB; Wang WJ; Philbin M; Niewoehner J; Damal K; Hansen RN
    Adv Ther; 2016 Aug; 33(8):1293-304. PubMed ID: 27324137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).
    Gold LS; Suh K; Schepman PB; Damal K; Hansen RN
    Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Repository-Corticotropin Injection (Acthar) in Refractory Juvenile Dermatomyositis: A Case Series.
    Pender TM; Patel AM; Rosenkranz ME
    J Clin Rheumatol; 2021 Dec; 27(8S):S405. PubMed ID: 32501940
    [No Abstract]   [Full Text] [Related]  

  • 6. Trends and Characteristics of US Medicare Spending on Repository Corticotropin.
    Hartung DM; Johnston K; Van Leuven S; Deodhar A; Cohen DM; Bourdette DN
    JAMA Intern Med; 2017 Nov; 177(11):1680-1682. PubMed ID: 28892525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acthar
    Kaplan J; Askanase A; Chu D; Abdellatif A; Basu D; Mirsaeidi M
    Clin Drug Investig; 2023 Oct; 43(10):739-761. PubMed ID: 37792273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.
    Hakim A; Gupta R; Ross JS
    JAMA; 2017 Dec; 318(22):2181-2182. PubMed ID: 29131905
    [No Abstract]   [Full Text] [Related]  

  • 10. Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?
    Hartung DM; Johnston K; Deodhar A; Bourdette DN; Cohen DM
    Am J Kidney Dis; 2019 Aug; 74(2):256-262. PubMed ID: 30765104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory inflames Centocor's profits.
    Glaser V
    Nat Biotechnol; 1998 Oct; 16(10):900. PubMed ID: 9788334
    [No Abstract]   [Full Text] [Related]  

  • 12. Health Care Rationing in a Just Society: The Clinical Effectiveness Model.
    Weisleder P
    Semin Pediatr Neurol; 2015 Sep; 22(3):201-4. PubMed ID: 26358431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 14. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes.
    Kutz C
    Ther Adv Chronic Dis; 2016 Jul; 7(4):190-7. PubMed ID: 27433309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy: Facing up to biosimilar agents--the ACR position.
    Scheinberg M
    Nat Rev Rheumatol; 2015 Jun; 11(6):322-4. PubMed ID: 25907701
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA OKs two new uses for biologic arthritis drug adalimumab.
    Health News; 2006 Jan; 12(1):2. PubMed ID: 16447312
    [No Abstract]   [Full Text] [Related]  

  • 17. How many types of patients meet classification criteria?
    Roth SH
    J Rheumatol; 1995 Jul; 22(7):1435; author reply 1435-6. PubMed ID: 7562792
    [No Abstract]   [Full Text] [Related]  

  • 18. Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree.
    Boers M
    Ann Intern Med; 2006 Jun; 144(12):933-5. PubMed ID: 16785481
    [No Abstract]   [Full Text] [Related]  

  • 19. Herbal remedies and drug interactions: an issue overlooked by health authorities.
    Cobert BL
    Expert Opin Drug Saf; 2006 Jan; 5(1):7. PubMed ID: 16370951
    [No Abstract]   [Full Text] [Related]  

  • 20. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
    Madan A; Mijovic-Das S; Stankovic A; Teehan G; Milward AS; Khastgir A
    BMC Nephrol; 2016 Mar; 17():37. PubMed ID: 27036111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.